Novavax (NVAX) has been struggling to convince the market that its COVID era gains can translate into a durable vaccine business, and the stock’s recent slide reflects those doubts. See our latest ...
Novavax, Inc. reported 3Q25 EPS loss & declining revenue, but beat revenue expectations & reaffirmed its FY25 guidance. Read ...
4don MSN
FDA Vaccine Chief Claims COVID Shots Linked to 'At Least 10' Child Deaths but Offers No Data
US FDA's vaccine director Dr. Vinay Prasad wrote a memo to their staff that claimed multiple child deaths were related to ...
Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...
The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain ...
The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is ...
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12. The Maryland-based company makes a protein-based vaccine that's been cleared for use in adults in parts ...
Meanwhile, Novavax has no approved products on the market. But it does have one late-stage candidate, a respiratory syncytial virus fusion (RSV F) protein nanoparticle vaccine. Novavax expects ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback